155 related articles for article (PubMed ID: 24320058)
21. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
[TBL] [Abstract][Full Text] [Related]
22. Localization of the VEGF and angiopoietin genes in uterine carcinosarcoma.
Emoto M; Charnock-Jones DS; Licence DR; Ishiguro M; Kawai M; Yanaihara A; Saito T; Hachisuga T; Iwasaki H; Kawarabayashi T; Smith SK
Gynecol Oncol; 2004 Dec; 95(3):474-82. PubMed ID: 15581949
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological and immunohistochemical characteristics of esophageal carcinosarcoma.
Sano A; Sakurai S; Kato H; Sakai M; Tanaka N; Inose T; Saito K; Sohda M; Nakajima M; Sakamoto K; Sano T; Hosoya Y; Enomoto T; Kanda T; Ajioka Y; Oyama T; Kuwano H
Anticancer Res; 2009 Aug; 29(8):3375-80. PubMed ID: 19661359
[TBL] [Abstract][Full Text] [Related]
24. Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study.
Sartori E; Bazzurini L; Gadducci A; Landoni F; Lissoni A; Maggino T; Zola P; La Face B
Gynecol Oncol; 1997 Oct; 67(1):70-5. PubMed ID: 9345359
[TBL] [Abstract][Full Text] [Related]
25. [Clinical features and prognosis of 25 cases of breast carcinosarcoma].
Yang YF; Liu J; Fang ZY; Gu L
Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):620-3. PubMed ID: 23158999
[TBL] [Abstract][Full Text] [Related]
26. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
[TBL] [Abstract][Full Text] [Related]
27. Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).
Edmondson RJ; O'Connell RL; Banerjee S; Mileshkin L; Sykes P; Beale P; Fisher A; Bonaventura A; Millan D; Nottley S; Benson C; Hamilton A; Sjoquist K; Alexander L; Kelly C; Carty K; Divers L; Bradshaw N; Friedlander M;
Gynecol Oncol; 2021 Dec; 163(3):524-530. PubMed ID: 34625284
[TBL] [Abstract][Full Text] [Related]
28. Review of Recommended Treatment of Uterine Carcinosarcoma.
Menczer J
Curr Treat Options Oncol; 2015 Nov; 16(11):53. PubMed ID: 26374341
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant Treatment Modalities, Prognostic Factors, and Outcome of the Uterine Carcinosarcoma.
Kahramanoglu I; Demirkiran F; Turan H; Bese T; Cebi S; Ilvan S; Arvas M
J Obstet Gynaecol Can; 2021 Jan; 43(1):34-42. PubMed ID: 33041218
[TBL] [Abstract][Full Text] [Related]
30. [Clinical analysis of 12 cases of uterine carcinosarcoma].
Wang LH; Xiong Y; Li YF; Li JD; Feng YL; Li YJ; Chen C; Chen L
Ai Zheng; 2008 May; 27(5):516-9. PubMed ID: 18479602
[TBL] [Abstract][Full Text] [Related]
31. Carcinosarcoma of the uterus: immunohistochemical and genetic analysis of clonality of one case.
Watanabe M; Shimizu K; Kato H; Imai H; Nakano H; Sugawa M; Shiraishi T
Gynecol Oncol; 2001 Sep; 82(3):563-7. PubMed ID: 11520156
[TBL] [Abstract][Full Text] [Related]
32. Nestin: A biomarker of aggressive uterine cancers.
Hope ER; Mhawech-Fauceglia P; Pejovic T; Zahn CM; Wang G; Conrads TP; Larry Maxwell G; Hamilton CA; Darcy KM; Syed V
Gynecol Oncol; 2016 Mar; 140(3):503-11. PubMed ID: 26718725
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases.
Ariyoshi K; Kawauchi S; Kaku T; Nakano H; Tsuneyoshi M
Histopathology; 2000 Nov; 37(5):427-36. PubMed ID: 11119124
[TBL] [Abstract][Full Text] [Related]
34. Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study.
Bodner-Adler B; Bodner K; Obermair A; Czerwenka K; Petru E; Leodolter S; Mayerhofer K
Anticancer Res; 2001; 21(4B):3069-74. PubMed ID: 11712812
[TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer.
Toi M; Inada K; Hoshina S; Suzuki H; Kondo S; Tominaga T
Clin Cancer Res; 1995 Sep; 1(9):961-4. PubMed ID: 9816067
[TBL] [Abstract][Full Text] [Related]
36. Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Saito A; Nishikawa T; Yoshida H; Mizoguchi C; Kitadai R; Yamamoto K; Yazaki S; Kojima Y; Ishikawa M; Kato T; Yonemori K
Gynecol Oncol; 2023 Sep; 176():115-121. PubMed ID: 37506533
[TBL] [Abstract][Full Text] [Related]
37. Identification of distinct molecular subtypes of uterine carcinosarcoma.
An Y; Wang H; Jie J; Tang Y; Zhang W; Ji S; Guo X
Oncotarget; 2017 Feb; 8(9):15878-15886. PubMed ID: 28178664
[TBL] [Abstract][Full Text] [Related]
38. Differential expression of matrix metalloprotease-7 in each component of uterine carcinosarcoma.
Tanimoto H; Shigemasa K; Sasaki M; Katayama H; Kusumi I; Parmley TH; O'Brien TJ; Ohama K
Oncol Rep; 2000; 7(6):1209-12. PubMed ID: 11032915
[TBL] [Abstract][Full Text] [Related]
39. OSucs: An Online Prognostic Biomarker Analysis Tool for Uterine Carcinosarcoma.
An Y; Wang Q; Sun F; Zhang G; Wang F; Zhang L; Li Y; Ren W; Zhu W; Li Y; Ji S; Guo X
Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32899312
[TBL] [Abstract][Full Text] [Related]
40. Angiogenesis and expression of angiogenic agents in uterine and ovarian carcinosarcomas.
Näyhä V; Stenbäck F
APMIS; 2008 Feb; 116(2):107-17. PubMed ID: 18321361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
